Comparing Eloxx Pharmaceuticals (ELOX) & Its Peers

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its dividends, valuation, analyst recommendations, institutional ownership, risk, earnings and profitability.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -3.16, suggesting that their average share price is 416% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-11.33
Eloxx Pharmaceuticals Competitors	$3.56 billion	$3.15 billion	544.95

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.57%	-16.98%

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Eloxx Pharmaceuticals and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	3	1	2.80
Eloxx Pharmaceuticals Competitors	7592	13654	25473	1001	2.42

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, indicating a potential upside of 119.68%. As a group, “Pharmaceuticals” companies have a potential upside of 27.57%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than its peers.

Summary

Eloxx Pharmaceuticals beats its peers on 8 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.